Skip to main
FULC

FULC Stock Forecast & Price Target

FULC Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 56%
Sell 22%
Strong Sell 0%

Bulls say

Fulcrum Therapeutics is currently facing challenges with their lead product candidate, pociredir, due to potential risks of secondary malignancies observed with the Polycomb Repressive Complex 2 (PRC2) class. However, the company has a strong pipeline of pre-clinical and clinical-stage programs targeting rare genetic diseases, which could lead to potential future revenue growth. While FULC has not set a timeline for completing their strategic alternatives plan, their experienced management team and focus on epigenetic regulation of gene expression make them a company to watch in the biopharmaceutical industry.

Bears say

Fulcrum Therapeutics is facing significant challenges following the discontinuation of pociredir for the treatment of sickle cell disease. The company is currently undergoing a strategic review to find alternative solutions, but it may be difficult to find a path forward after the FDA's heightened concerns regarding the potential malignancy risks associated with PRC2 inhibition. Additionally, Fulcrum will have to reduce operating expenses to preserve its cash position, which could impact its ability to continue developing its pipeline of products. As such, it may be prudent for investors to have a negative outlook on the company until they can demonstrate a viable path forward and address these challenges.

FULC has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 56% suggest Holding, 22% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fulcrum Therapeutics Inc (FULC) Forecast

Analysts have given FULC a Hold based on their latest research and market trends.

According to 9 analysts, FULC has a Hold consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fulcrum Therapeutics Inc (FULC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.